Analytical aspects of meet-in-metabolite analysis for molecular pathway reconstitution from exposure to adverse outcome

Mol Aspects Med. 2022 Oct:87:101006. doi: 10.1016/j.mam.2021.101006. Epub 2021 Jul 23.

Abstract

To explore the etiology of diseases is one of the major goals in epidemiological study. Meet-in-metabolite analysis reconstitutes biomonitoring-based adverse outcome (AO) pathways from environmental exposure to a disease, in which the chemical exposome-related metabolism responses are transmitted to incur the AO-related metabolism phenotypes. However, the ongoing data-dependent acquisition of non-targeted biomonitoring by high-resolution mass spectrometry (HRMS) is biased against the low abundance molecules, which forms the major of molecular internal exposome, i.e., the totality of trace levels of environmental pollutants and/or their metabolites in human samples. The recent development of data-independent acquisition protocols for HRMS screening has opened new opportunities to enhance unbiased measurement of the extremely low abundance molecules, which can encompass a wide range of analytes and has been applied in metabolomics, DNA, and protein adductomics. In addition, computational MS for small molecules is urgently required for the top-down exposome databases. Although a holistic analysis of the exposome and endogenous metabolites is plausible, multiple and flexible strategies, instead of "putting one thing above all" are proposed.

Keywords: Adverse outcome pathway; Human biomonitoring; Metabolome; Molecular exposome; Non-targeted analysis; System epidemiology.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Environmental Exposure* / adverse effects
  • Humans
  • Mass Spectrometry
  • Metabolome
  • Metabolomics* / methods